Top

Published in:

01-01-2014 | Research Paper

Tumour growth stimulation following partial hepatectomy in mice is associated with increased upregulation of c-Met

Authors: Nadia Harun, Patricia Costa, C. Christophi

Published in: Clinical & Experimental Metastasis | Issue 1/2014

Abstract

Hepatic resection is the preferred option for curative treatment of colorectal liver metastasis (CLM). However, this is associated with significant recurrence rates in both hepatic and extrahepatic sites. The upregulation of growth factors required for liver regeneration after resection is thought to stimulate the growth of micrometastases. The current study describes temporal changes in the expression of hepatocyte growth factor receptor (c-Met), epidermal growth factor receptor (EGFR) and insulin growth factor I receptor (IGF-IR) in an orthotopic mouse model of liver resection and tumour induction. Mice underwent 70 % hepatectomy and induction of liver metastases through intrasplenic injection of colorectal cancer cells. Control groups included sham-operated mice and 70 % hepatectomy alone. The expression levels of liver and tumour c-Met, EGFR and IGF-IR were quantified by quantitative RT-PCR at different time points. 70 % liver resection stimulates tumour growth; increases the expression of c-Met within established tumours and surrounding liver parenchyma; downregulates EGFR expression and increases IGF-IR expression within the liver parenchyma. In conclusion, we demonstrate in our mouse model that major hepatectomy stimulates engraftment and growth of CLM and that this effect is probably due to the upregulation of c-Met as a result of the liver regeneration process. Liver IGF-IR may also contribute to this phenomenon through a paracrine effect on tumour growth. This study provides support for the role of c-Met in the stimulation of tumour growth after resection possibly through the promotion of tumour cell proliferation.

Saenz NC, Cady B, McDermott WV Jr, Steele GD Jr (1989) Experience with colorectal carcinoma metastatic to the liver. Surg Clin North Am 69(2):361–370PubMed

Pestana C, Reitemeier RJ, Moertel CG, Judd ES, Dockerty MB (1964) The natural history of carcinoma of the colon and rectum. Am J Surg 108:826–829PubMedCrossRef

Koh SL, Ager EI, Christophi C (2010) Liver regeneration and tumour stimulation: implications of the renin-angiotensin system. Liver Int 30(10):1414–1426. doi:10.1111/j.1478-3231.2010.02306.x PubMedCrossRef

Christophi C, Harun N, Fifis T (2008) Liver regeneration and tumor stimulation–a review of cytokine and angiogenic factors. J Gastrointest Surg 12(5):966–980. doi:10.1007/s11605-007-0459-6 PubMedCrossRef

de Jong MC, Pulitano C, Ribero D, Strub J, Mentha G, Schulick RD, Choti MA, Aldrighetti L, Capussotti L, Pawlik TM (2009) Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg 250(3):440–448. doi:10.1097/SLA.0b013e3181b4539b PubMed

Lukomska B, Dluzniewska J, Polanski J, Zajac L (2004) Expression of growth factors in colorectal carcinoma liver metastatic patients after partial hepatectomy: implications for a functional role in cell proliferation during liver regeneration. Comp Hepatol 3(1):S52. doi:10.1186/1476-5926-2-S1-S521476-5926-2-S1-S52 PubMedCentralPubMedCrossRef

Dluzniewska J, Zolich D, Polanski J, Zajac L, Sitkiewicz D, Lukomska B (2002) Hepatocyte growth factor levels in liver and blood, and post-operative liver cell proliferation in patients with benign and malignant liver tumors after partial hepatectomy. Med Sci Monit 8(10):690–696

Yoon SS, Kim SH, Gonen M, Heffernan NM, Detwiller KY, Jarnagin WR, D’Angelica M, Blumgart LH, Tanabe KK, Dematteo RP (2006) Profile of plasma angiogenic factors before and after hepatectomy for colorectal cancer liver metastases. Ann Surg Oncol 13(3):353–362. doi:10.1245/ASO.2006.03.060 PubMedCrossRef

Rupertus K, Kollmar O, Scheuer C, Junker B, Menger MD, Schilling MK (2007) Major but not minor hepatectomy accelerates engraftment of extrahepatic tumor cells. Clin Exp Metastasis 24(1):39–48. doi:10.1007/s10585-006-9054-6 PubMedCrossRef

10.

Huh CG, Factor VM, Sanchez A, Uchida K, Conner EA, Thorgeirsson SS (2004) Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci USA 101(13):4477–4482. doi:10.1073/pnas.0306068101 PubMedCrossRef

11.

Michalopoulos GK, Khan Z (2005) Liver regeneration, growth factors, and amphiregulin. Gastroenterology 128(2):503–506PubMedCentralPubMedCrossRef

12.

Natarajan A, Wagner B, Sibilia M (2007) The EGF receptor is required for efficient liver regeneration. Proc Natl Acad Sci USA 104(43):17081–17086. doi:10.1073/pnas.0704126104 PubMedCrossRef

13.

Bohm F, Kohler UA, Speicher T, Werner S (2010) Regulation of liver regeneration by growth factors and cytokines. EMBO Mol Med 2(8):294–305. doi:10.1002/emmm.201000085 PubMedCentralPubMedCrossRef

14.

Factor VM, Seo D, Ishikawa T, Kaposi-Novak P, Marquardt JU, Andersen JB, Conner EA, Thorgeirsson SS (2010) Loss of c-Met disrupts gene expression program required for G2/M progression during liver regeneration in mice. PLoS One 5(9):e12739. doi:10.1371/journal.pone.0012739 PubMedCentralPubMedCrossRef

15.

Desbois-Mouthon C, Wendum D, Cadoret A, Rey C, Leneuve P, Blaise A, Housset C, Tronche F, Le Bouc Y, Holzenberger M (2006) Hepatocyte proliferation during liver regeneration is impaired in mice with liver-specific IGF-1R knockout. FASEB J 20(6):773–775. doi:10.1096/fj.05-4704fje PubMed

16.

Peruzzi B, Bottaro DP (2006) Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 12(12):3657–3660. doi:10.1158/1078-0432.CCR-06-0818 PubMedCrossRef

17.

Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R (2002) Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev 13(1):41–59PubMedCrossRef

18.

Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS (2006) Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366(1):2–16. doi:10.1016/j.gene.2005.10.018 PubMedCrossRef

19.

Dvorak HF, Detmar M, Claffey KP, Nagy JA, van de Water L, Senger DR (1995) Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. Int Arch Allergy Immunol 107(1–3):233–235PubMedCrossRef

20.

Hellstrom I, Hellstrom KE, Nishioka M (1975) Reactivity to tumour-associated antigens detected in mice undergoing liver regeneration. Nat 253(5494):744–746CrossRef

21.

Picardo A, Karpoff HM, Ng B, Lee J, Brennan MF, Fong Y (1998) Partial hepatectomy accelerates local tumor growth: potential roles of local cytokine activation. Surg 124(1):57–64. doi:S0039606098002025 CrossRef

22.

Asaga T, Suzuki K, Umeda M, Sugimasa Y, Takemiya S, Okamoto T (1991) The enhancement of tumor growth after partial hepatectomy and the effect of sera obtained from hepatectomized rats on tumor cell growth. Jpn J Surg 21(6):669–675PubMedCrossRef

23.

Krause P, Flikweert H, Monin M, Seif Amir Hosseini A, Helms G, Cantanhede G, Ghadimi BM, Koenig S (2013) Increased growth of colorectal liver metastasis following partial hepatectomy. Clin Exp Metastasis 30(5):681–693. doi:10.1007/s10585-013-9572-y PubMedCentralPubMedCrossRef

24.

Harun N, Nikfarjam M, Muralidharan V, Christophi C (2007) Liver regeneration stimulates tumor metastases. J Surg Res 138(2):284–290. doi:10.1016/j.jss.2006.06.024 PubMedCrossRef

25.

Neo JH, Malcontenti-Wilson C, Muralidharan V, Christophi C (2007) Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases. J Gastroenterol Hepatol 22(4):577–584. doi:10.1111/j.1440-1746.2006.04797.x PubMedCrossRef

26.

Kuruppu D, Christophi C, Bertram JF, O’Brien PE (1996) Characterization of an animal model of hepatic metastasis. J Gastroenterol Hepatol 11(1):26–32PubMedCrossRef

27.

Nagel JD, Kort WJ (1992) A new liver-tumor model in the rat. Cancer Chemother Pharmacol 30(1):70–72PubMedCrossRef

28.

Nikfarjam M, Malcontenti-Wilson C, Fanartzis M, Daruwalla J, Christophi C (2004) A model of partial hepatectomy in mice. J Invest Surg 17(5):291–294. doi:10.1080/0894193049050287158K3BR487URA1N6N PubMedCrossRef

29.

Ager EI, Chong WW, Wen SW, Christophi C (2010) Targeting the angiotensin II type 2 receptor (AT2R) in colorectal liver metastases. Cancer Cell Int 10:19. doi:10.1186/1475-2867-10-19 PubMedCentralPubMedCrossRef

30.

Stolz DB, Mars WM, Petersen BE, Kim TH, Michalopoulos GK (1999) Growth factor signal transduction immediately after two-thirds partial hepatectomy in the rat. Cancer Res 59(16):3954–3960PubMed

31.

Meredith K, Haemmerich D, Qi C, Mahvi D (2007) Hepatic resection but not radiofrequency ablation results in tumor growth and increased growth factor expression. Ann Surg 245(5):771–776. doi:10.1097/01.sla.0000261319.51744.59 PubMedCrossRef

32.

Lim C, Cauchy F, Azoulay D, Farges O, Ronot M, Pocard M (2013) Tumour progression and liver regeneration-insights from animal models. Nat Rev Gastroenterol Hepatol. doi:10.1038/nrgastro.2013.55 PubMed

33.

Tanaka K, Hiroshima Y, Nakagawa K, Kumamoto T, Nojiri K, Takeda K, Ota M, Ichikawa Y, Endo I (2013) Two-stage hepatectomy with effective perioperative chemotherapy does not induce tumor growth or growth factor expression in liver metastases from colorectal cancer. Surg 153(2):179–188. doi:10.1016/j.surg.2012.06.026 CrossRef

34.

Stolz DB, Ross MA, Salem HM, Mars WM, Michalopoulos GK, Enomoto K (1999) Cationic colloidal silica membrane perturbation as a means of examining changes at the sinusoidal surface during liver regeneration. Am J Pathol 155(5):1487–1498. doi:10.1016/S0002-9440(10)65464-8 PubMedCrossRef

35.

Michalopoulos GK, DeFrances MC (1997) Liver regeneration. Sci 276(5309):60–66CrossRef

36.

Ross MA, Sander CM, Kleeb TB, Watkins SC, Stolz DB (2001) Spatiotemporal expression of angiogenesis growth factor receptors during the revascularization of regenerating rat liver. Hepatol 34(6):1135–1148. doi:10.1053/jhep.2001.29624 CrossRef

37.

Borowiak M, Garratt AN, Wustefeld T, Strehle M, Trautwein C, Birchmeier C (2004) Met provides essential signals for liver regeneration. Proc Natl Acad Sci U S A 101(29):10608–10613. doi:10.1073/pnas.0403412101 PubMedCentralPubMedCrossRef

38.

Santos A, Yusta B, Fernandez-Moreno MD, Blazquez E (1994) Expression of insulin-like growth factor-I (IGF-I) receptor gene in rat brain and liver during development and in regenerating adult rat liver. Mol Cell Endocrinol 101(1–2):85–93PubMedCrossRef

39.

Michalopoulos GK (2010) Liver regeneration after partial hepatectomy: critical analysis of mechanistic dilemmas. Am J Pathol 176(1):2–13. doi:10.2353/ajpath.2010.090675 PubMedCrossRef

40.

Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N (1995) Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 95(4):1789–1797. doi:10.1172/JCI117857 PubMedCentralPubMedCrossRef

41.

Baker CH, Kedar D, McCarty MF, Tsan R, Weber KL, Bucana CD, Fidler IJ (2002) Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas. Am J Pathol 161(3):929–938. doi:10.1016/S0002-9440(10)64253-8 PubMedCrossRef

42.

Wu Y, Yakar S, Zhao L, Hennighausen L, LeRoith D (2002) Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res 62(4):1030–1035PubMed

43.

Winder T, Lenz HJ (2010) Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer. Gastroenterol 138(6):2163–2176. doi:10.1053/j.gastro.2010.02.005 CrossRef

44.

Bid HK, Zhan J, Phelps DA, Kurmasheva RT, Houghton PJ (2012) Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2. Mol Cancer Ther 11(3):649–659. doi:10.1158/1535-7163.MCT-11-0575 PubMedCentralPubMedCrossRef

45.

Di Renzo MF, Olivero M, Giacomini A, Porte H, Chastre E, Mirossay L, Nordlinger B, Bretti S, Bottardi S, Giordano S et al (1995) Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res 1(2):147–154PubMed

46.

De Oliveira AT, Matos D, Logullo AF, DAS SR, Neto RA, Filho AL, Saad SS (2009) MET Is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality. Anticancer Res 29(11):4807–4811PubMed

47.

Sierra JR, Tsao MS (2011) c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol 3(1):S21–S35. doi:10.1177/1758834011422557 PubMedCentralPubMedCrossRef

48.

Efferth T (2012) Signal transduction pathways of the epidermal growth factor receptor in colorectal cancer and their inhibition by small molecules. Curr Med Chem 19(33):5735–5744PubMedCrossRef

49.

Ewing GP, Goff LW (2010) The insulin-like growth factor signaling pathway as a target for treatment of colorectal carcinoma. Clin Colorectal Cancer 9(4):219–223. doi:10.3816/CCC.2010.n.032 PubMedCrossRef

50.

Horiguchi N, Takayama H, Toyoda M, Otsuka T, Fukusato T, Merlino G, Takagi H, Mori M (2002) Hepatocyte growth factor promotes hepatocarcinogenesis through c-Met autocrine activation and enhanced angiogenesis in transgenic mice treated with diethylnitrosamine. Oncog 21(12):1791–1799. doi:10.1038/sj.onc.1205248 CrossRef

51.

Casanova ML, Larcher F, Casanova B, Murillas R, Fernandez-Acenero MJ, Villanueva C, Martinez-Palacio J, Ullrich A, Conti CJ, Jorcano JL (2002) A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis. Cancer Res 62(12):3402–3407PubMed

52.

Xue M, Cao X, Zhong Y, Kuang D, Liu X, Zhao Z, Li H (2012) Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors in cancer therapy: advances and perspectives. Curr Pharm Des 18(20):2901–2913PubMedCrossRef

53.

Pietras K, Pahler J, Bergers G, Hanahan D (2008) Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med 5(1):e19. doi:10.1371/journal.pmed.0050019 PubMedCentralPubMedCrossRef

54.

Fifis T, Malcontenti-Wilson C, Amijoyo J, Anggono B, Muralidharan V, Nikfarjam M, Christophi C (2011) Changes in growth factor levels after thermal ablation in a murine model of colorectal liver metastases. HPB 13(4):246–255. doi:10.1111/j.1477-2574.2010.00278.x PubMedCentralPubMedCrossRef

55.

Wu F, Wu L, Zheng S, Ding W, Teng L, Wang Z, Ma Z, Zhao W (2006) The clinical value of hepatocyte growth factor and its receptor–c-met for liver cancer patients with hepatectomy. Dig Liver Dis 38(7):490–497. doi:10.1016/j.dld.2006.03.007 PubMedCrossRef

56.

Osada S, Matsui S, Komori S, Yamada J, Sanada Y, Ihawa A, Tanaka Y, Tokuyama Y, Okumura N, Nonaka K, Hosono Y, Takahashi T, Yamaguchi K, Yoshida K (2010) Effect of hepatocyte growth factor on progression of liver metastasis in colorectal cancer. Hepatogastroenterol 57(97):76–80

57.

Greenall SA, Gherardi E, Liu Z, Donoghue JF, Vitali AA, Li Q, Murphy R, Iamele L, Scott AM, Johns TG (2012) Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET. PLoS ONE 7(4):e34658. doi:10.1371/journal.pone.0034658 PubMedCentralPubMedCrossRef

58.

de Jong GM, Hendriks T, Eek A, Oyen WJ, Nagtegaal ID, Bleichrodt RP, Boerman OC (2011) Adjuvant radioimmunotherapy improves survival of rats after resection of colorectal liver metastases. Ann Surg 253(2):336–341. doi:10.1097/SLA.0b013e3181ff313a PubMedCrossRef

59.

Wu Y, Brodt P, Sun H, Mejia W, Novosyadlyy R, Nunez N, Chen X, Mendoza A, Hong SH, Khanna C, Yakar S (2010) Insulin-like growth factor-I regulates the liver microenvironment in obese mice and promotes liver metastasis. Cancer Res 70(1):57–67. doi:10.1158/0008-5472.CAN-09-2472 PubMedCrossRef

60.

Karpoff HM, Tung C, Ng B, Fong Y (1996) Interferon gamma protects against hepatic tumor growth in rats by increasing Kupffer cell tumoricidal activity. Hepatol 24(2):374–379. doi:S027091399600333310.1002/hep.510240214 CrossRef

61.

Ono M, Tanaka N, Orita K (1986) Complete regression of mouse hepatoma transplanted after partial hepatectomy and the immunological mechanism of such regression. Cancer Res 46(10):5049–5053PubMed

Title: Tumour growth stimulation following partial hepatectomy in mice is associated with increased upregulation of c-Met
Authors: Nadia Harun
Patricia Costa
C. Christophi
Publication date: 01-01-2014
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 1/2014
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-013-9604-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel

Mapping protein signal pathway interaction in sarcoma bone metastasis: linkage between rank, metalloproteinases turnover and growth factor signaling pathways

Prolonged survival following aggressive treatment for metastatic breast cancer in the spine

Melanoma brain metastases: the impact of nodal disease

The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma

Relaxins enhance growth of spontaneous murine breast cancers as well as metastatic colonization of the brain

Keynote webinar | Spotlight on antibody–drug conjugates in cancer